Vicarious Surgical (RBOT) 10-Q 9 May 22 2022 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 04, 2022
Document Information Line Items
Entity Registrant Name	VICARIOUS SURGICAL INC.
Trading Symbol	RBOT
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001812173
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-39384
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-2678169
Entity Address, Address Line One	78 Fourth Avenue
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02451
Title of 12(b) Security	Class A common stock, $0.0001 par value per share
Security Exchange Name	NYSE
Entity Interactive Data Current	Yes
City Area Code	617
Local Phone Number	8681700
Class A Common Stock
Document Information Line Items
Entity Common Stock, Shares Outstanding		101,454,717
Class B Common Stock
Document Information Line Items
Entity Common Stock, Shares Outstanding		19,789,860

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 157,011	$ 173,507
Prepaid expenses and other current assets	3,852	4,867
Total current assets	160,863	178,374
Restricted cash	936	1,055
Property and equipment, net	4,087	2,250
Right-of-use assets	14,085
Total assets	179,971	181,679
Current liabilities:
Accounts payable	2,118	1,500
Accrued expenses	3,045	4,098
Lease liabilities, current portion	580
Current portion of equipment loans	47	47
Current portion of term loan	600	600
Total current liabilities	6,390	6,245
Lease liabilities, net of current portion	15,520
Deferred rent		1,631
Equipment loans, net of current portion	4	16
Term loan, net of current portion and issuance costs	534	675
Warrant liabilities	29,292	90,021
Total liabilities	51,740	98,588
Commitments and Contingencies (Note 8)
Legacy convertible preferred stock (Note 11)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; no shares issued or outstanding at March 31, 2022 and December 31, 2021
Class A Common stock, $0.0001 par value; 300,000,000 shares authorized at March 31, 2022 and December 31, 2021; 101,378,795 and 99,979,207 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	10	10
Class B Common stock, $0.0001 par value; 22,000,000 shares authorized at March 31, 2022 and December 31, 2021; 19,789,860 shares issued and outstanding at March 31, 2022 and December 31, 2021	2	2
Additional paid-in capital	152,490	149,877
Accumulated deficit	(24,271)	(66,798)
Total stockholders’ equity	128,231	83,091
Total liabilities and stockholders’ equity	$ 179,971	$ 181,679

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.0001
Class A Common Stock
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	101,378,795	99,979,207
Common stock, shares outstanding	101,378,795	99,979,207
Class B Common Stock
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	22,000,000	22,000,000
Common stock, shares issued	19,789,860	19,789,860
Common stock, shares outstanding	19,789,860	19,789,860

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 9,848	$ 3,607
Sales and marketing	1,402	226
General and administrative	6,930	1,398
Total operating expenses	18,180	5,231
Loss from operations	(18,180)	(5,231)
Other income (expense):
Change in fair value of warrant liabilities	60,728
Interest income	8	1
Interest expense	(29)	(1)
Income/(loss) before income taxes	42,527	(5,231)
Provision for income taxes
Net income/(loss) and comprehensive gain/(loss)	$ 42,527	$ (5,231)
Net income/(loss) per share of Class A and Class B common stock, basic (in Dollars per share)	$ 0.35	$ (0.06)
Net income/(loss) per share of Class A and Class B common stock, diluted (in Dollars per share)	$ 0.33	$ (0.06)

Condensed Consolidated Statem_2

Condensed Consolidated Statements Of Convertible Preferred Stock, Common Stock And Stockholders’ Equity/(Deficit) (Unaudited) - USD ($) $ in Thousands	Class A & BCommon Stock	Convertible Preferred Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2020	$ 2	$ 46,670	$ 1,772	$ (31,591)	$ (29,817)
Balance (in Shares) at Dec. 31, 2020	20,662,068	66,550,929
Retroactive application of recapitalization (Note 1)	$ 7	$ (46,670)	46,663		46,670
Retroactive application of recapitalization (Note 1) (in Shares)	66,550,929	(66,550,929)
Adjusted balance, beginning of period	$ 9		48,435	(31,591)	16,853
Adjusted balance, beginning of period (in Shares)	87,212,997
Exercise of common stock options			56		56
Exercise of common stock options (in Shares)	246,476
Vesting of restricted stock (in Shares)	217,603
Stock-based compensation			256		256
Net income (Loss)				(5,231)	(5,231)
Balance at Mar. 31, 2021	$ 9		48,747	(36,822)	11,934
Balance (in Shares) at Mar. 31, 2021	87,677,076
Balance at Dec. 31, 2021	$ 12		149,877	(66,798)	83,091
Balance (in Shares) at Dec. 31, 2021	119,769,067
Exercise of common stock options			336		336
Exercise of common stock options (in Shares)	1,342,852
Exercise of public warrants (in Shares)	20
Vesting of restricted stock (in Shares)	56,716
Stock-based compensation			2,277		2,277
Net income (Loss)				42,527	42,527
Balance at Mar. 31, 2022	$ 12		$ 152,490	$ (24,271)	$ 128,231
Balance (in Shares) at Mar. 31, 2022	121,168,655

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net income/(loss)	$ 42,527	$ (5,231)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	185	41
Stock-based compensation	2,277	256
Amortization of capitalized debt issuance costs	8
Non-cash lease expense	217
Change in fair value of warrant liabilities	(60,728)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	1,015	(164)
Accounts payable	618	132
Accrued expenses	(1,053)	827
Lease liabilities	167
Deferred rent		(1)
Net cash used in operating activities	(14,767)	(4,140)
Cash flows from investing activities:
Purchases of property and equipment	(2,022)	(128)
Net cash (used in)/provided by investing activities	(2,022)	(128)
Cash flows from financing activities:
Repayment of equipment loans	(12)	(8)
Proceeds from term loan		1,500
Repayment of term loan	(150)
Proceeds from exercise of stock options	336	56
Net cash provided by financing activities	174	1,548
Change in cash, cash equivalents and restricted cash	(16,615)	(2,720)
Cash, cash equivalents and restricted cash, beginning of period	174,562	16,985
Cash, cash equivalents and restricted cash, end of period	157,947	14,265
Reconciliation of restricted cash:
Cash and cash equivalents	157,011	13,643
Restricted cash	936	622
Reconciliation of restricted cash total	157,947	14,265
Supplemental cash flow information:
Interest paid	$ 11	1
Non-cash investing and financing activities:
Issuance of warrants recorded as deferred financing costs		$ 85

Nature of Business and Basis of

Nature of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
NATURE OF BUSINESS AND BASIS OF PRESENTATION	1. NATURE OF BUSINESS AND BASIS OF PRESENTATION Nature of Business Vicarious Surgical Inc. (“Vicarious” or the “Company”) was incorporated in the state of Delaware on May 1, 2014, and is headquartered in Waltham, Massachusetts. The Company is currently developing its virtual reality surgical system using proprietary human-like surgical robots and virtual reality to transport surgeons inside the patient to perform minimally invasive surgical procedures. The accompanying condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative US GAAP. Unless otherwise indicated or the context otherwise requires, references in this Quarterly Report on Form 10-Q to the “Company” and “Vicarious Surgical” refer to the consolidated operations of Vicarious Surgical Inc. References to “D8” refer to the Company prior to the consummation of the Business Combination and references to “Legacy Vicarious Surgical” refer to Vicarious Surgical Inc. prior to the consummation of the Business Combination. On April 15, 2021, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with D8 Holdings Corp (“D8”) to effect a business combination between D8 and the Company with the Company surviving the merger as a wholly owned subsidiary of D8 (the “Business Combination”). On September 17, 2021 the Merger Agreement was effected, and each share of Vicarious Surgical Inc. stock was exchanged for 3.29831 shares of D8 common stock. The Company received total proceeds of $77,993 after redemptions. In connection with the Business Combination, D8 entered into subscription agreements with subscribers who agreed to purchase an aggregate of 14,200,000 shares of Class A common stock for a purchase price of $142,000 (the “PIPE”), all of which were issued on the effective date. In total, this provided the Company cash of $190,424, which is net of transaction costs of $29,569. Legacy Vicarious Surgical was deemed to be the accounting acquirer in the Business Combination. The determination was primarily based on Legacy Vicarious Surgical’s stockholders having a majority of the voting power in the combined Company, Legacy Vicarious Surgical having the ability to appoint a majority of the Board of Directors of the Company, Legacy Vicarious Surgical’s existing management team comprising the senior management of the combined Company, Legacy Vicarious Surgical comprising the ongoing operations of the combined Company and the combined Company assuming Vicarious Surgical’s name. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Legacy Vicarious Surgical issuing stock for the net assets of D8, accompanied by a recapitalization. The net assets of D8 are stated at historical cost, with no goodwill or other intangible assets recorded. While D8 was the legal acquirer in the Business Combination, because Legacy Vicarious Surgical was deemed the accounting acquirer, the historical financial statements of Legacy Vicarious Surgical became the historical financial statements of the combined Company upon the consummation of the Business Combination. As a result, the financial statements included in this report reflect (i) the historical operating results of Legacy Vicarious Surgical prior to the Business Combination; (ii) the combined results of D8 and Legacy Vicarious Surgical following the close of the Business Combination; (iii) the assets and liabilities of Legacy Vicarious Surgical at their historical cost; and (iv) the Legacy Vicarious Surgical’s equity structure for all periods presented, as affected by the recapitalization presentation. In accordance with guidance applicable to these circumstances, the equity structure has been restated in all comparable periods up to September 17, 2021, to reflect the number of shares of the Company’s common stock, $0.0001 par value per share, issued to Legacy Vicarious Surgical’s stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to Legacy Vicarious Surgical’s outstanding convertible preferred stock and Legacy Vicarious Surgical’s common stock prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio of 3.29831 established in the Business Combination. Legacy Vicarious Surgical’s convertible preferred stock previously classified as mezzanine was retroactively adjusted, converted into common stock and reclassified to permanent as a result of the reverse recapitalization. Basis of Presentation The accompanying condensed consolidated financial statements are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the condensed consolidated financial statements prepared in accordance with US GAAP may have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes for the years ended December 31, 2021 and 2020. The condensed consolidated balance sheet as of December 31, 2021, included herein, was derived from the audited consolidated financial statements of the Company. The condensed consolidated financial statements, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, necessary to present fairly our financial position as of March 31, 2022, our results of operations, and stockholders’ equity for the three months ended March 31, 2022 and 2021, and our cash flows for the three-month periods ended March 31, 2022 and 2021. The operating results for the three-month period ended March 31, 2022 is not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any interim period or for any other future year. Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accompanying condensed consolidated financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere in the accompanying condensed consolidated financial statements and notes. Use of Estimates The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods presented. Estimates are used for, but are not limited to, the Company’s ability to continue as a going concern, depreciation of property and equipment, fair value of financial instruments, and contingencies. Actual results may differ from those estimates. Fair Value of Financial Instruments US GAAP requires disclosure of fair value information about financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. The framework provides a fair value hierarchy that prioritizes the inputs for the valuation techniques. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements) and minimizes the use of unobservable inputs. The most observable inputs are used, when available. The three levels of the fair value hierarchy are described as follows: Level 1 Level 2 Level 3 The carrying values of prepaid expenses, right of use assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of the instruments. The fair value of Public Warrants was determined from their trading value on public markets. The fair value of Private Placement Warrants was calculated using the Black-Scholes Option Pricing Model since these instruments do not have the early redemption feature. Cash and Cash Equivalents Cash and cash equivalents consist of checking accounts and money market funds. The Company considers all highly liquid investments with an original maturity of 90 days or less at the date of purchase to be cash equivalents. Restricted Cash The Company has an agreement to maintain a cash balance of $936 and $1,055 at March 31, 2022 and December 31, 2021, respectively as collateral for letters of credit related to the Company’s leases. The balance is classified as long-term on the Company’s balance sheets as the lease periods end beginning in December 2023 through February 2029. Short-Term Investments All of the Company’s investments, which consist of certificates of deposit, are classified as available for sale and are carried at fair value. There were no unrealized gains for the three month period ended March 31, 2022 and year ended December 31, 2021. The Company holds no short-term investments as of March 31, 2022. Concentrations of Credit Risk and Off-Balance-Sheet Risk The Company has no significant off-balance-sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist mainly of cash and cash equivalents. The Company maintains its cash and cash equivalents principally with accredited financial institutions of high-credit standing. Warrant Liabilities The Company does not use derivative instruments to hedge its exposures to cash flow, market or foreign currency risks. Management evaluates all of the Company’s financial instruments, including issued warrants to purchase its Class A common stock, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. As part of the Business Combination, the Company assumed 17,249,991 Public Warrants that are exercisable to purchase shares of Class A common stock to investors as well as 10,400,000 Private Placement Warrants. All of the Company’s outstanding warrants are recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, the Company recognizes the warrants as liabilities at fair value and adjusts the warrant liability to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the statement of operations. The fair value of Public Warrants was determined from their trading value on public markets. The fair value of Private Placement Warrants was calculated using the Black-Scholes Option Pricing Model since these instruments do not have the early redemption feature. Property and Equipment Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in the determination of net loss. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets. Impairment of Long-Lived Assets The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. The Company does not believe that any events have occurred through March 31, 2022, that would indicate its long-lived assets are impaired. Leases Prior to January 1, 2022, the Company accounted for leases under Accounting Standards Codification (“ASC”) 840, Leases Effective January 1, 2022, the Company adopted Accounting Standards Update (“ASU”) 2016-02, Leases The adoption of ASC 842 requires lessees to record a lease liability which is initially measured at the present value of all future lease payments, and a right-of-use asset, associated with operating leases, is recorded on the Company’s balance sheet. The standard also requires a single lease expense to be recognized within the statement of operations on a straight-line basis over the lease term. The effects of the Company’s January 1, 2022 adoption of ASC 842 resulted in the Company recording lease liabilities and right-of-use assets associated with its operating leases on its consolidated balance sheet and did not have any effect on the consolidated statement of operations or consolidated statement of cash flows. As part of the adoption of ASC 842, the Company elected to use the package of practical expedients permitted under the transition guidance. As a result, the Company did not reassess (i) whether any expired or existing contracts are or contain leases, (ii) the lease classification for any expired or existing leases, or (iii) initial direct costs for any existing leases. For each asset class and the related lease agreements in which the Company is the lessee that include lease and non-lease components, the Company made an election about the use of the practical expedient on all leases entered into or modified after January 1, 2022 to combine lease and non-lease components. Additionally, the Company elected to not record on the balance sheet leases with a term of twelve months or less. Guarantees and Indemnifications As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through March 31, 2022, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related liabilities have been established. Research and Development Research and development costs are expensed in the period incurred. Research and development costs include payroll and personnel expenses, consulting costs, software and webservices, legal, raw materials and allocated overhead such as depreciation and amortization, rent and utilities. Advance payments for goods and services to be used in future research and development activities are recorded as prepaid expenses and are expensed over the service period as the services are provided or when the goods are consumed. Stock-Based Compensation The Company accounts for all stock-based compensation, including stock options and warrants issued as compensation for services, at fair value and recognizes stock-based compensation expense for those equity awards, net of actual forfeitures, over the requisite service period, which is generally the vesting period of the respective award. The fair value of the Company’s stock options and warrants on the date of grant is determined by a Black-Scholes pricing model utilizing key assumptions such as stock price, expected volatility and expected term. The Company’s estimates of these assumptions are primarily based on the fair value of the Company’s stock, historical data, peer company data and judgment regarding future trends. Prior to becoming a publicly traded company, the fair value of the Company’s common stock was determined by the Board of Directors at each award grant date based upon a variety of factors, including the results obtained from an independent third-party valuation, the Company’s financial position and historical financial performance, the status of technological developments within the Company’s proposed products, the illiquid nature of the common stock, arm’s length sales of the Company’s capital stock, including convertible preferred stock, the effect of the rights and preferences of the preferred stockholders, and the prospects of a liquidity event, among others, as the Company’s common stock is was not actively traded. Since becoming a publicly traded company, the Company uses its publicly traded stock price as the fair value of its common stock. Income Taxes The Company accounts for income taxes under the asset and liability method pursuant to ASC 740, Accounting for Income Taxes The Company recognizes deferred tax assets to the extent that management believes that these assets are more likely than not to be realized in the future. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. The Company provides reserves for potential payments of taxes to various tax authorities related to uncertain tax positions. Amounts recognized are based on a determination of whether a tax benefit taken by the Company in its tax filings or positions is “more likely than not” to be sustained on audit. The amount recognized is equal to the largest amount that is more than 50% likely to be sustained. Interest and penalties associated with uncertain tax positions are recorded as a component of income tax expense. Net Income/(Loss) Per Share Basic net income/(loss) per share attributable to common stockholders is computed by dividing the net income/(loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted income/(loss) per share attributable to common stockholders is computed by dividing the diluted net income/(loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common stock. For purpose of this calculation, outstanding stock options, restricted stock units and stock warrants are considered potential dilutive common stock and are excluded from the computation of net loss per share as their effect is anti-dilutive. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to be outstanding when their effect is anti-dilutive. Comprehensive Income/(Loss) There were no differences between net income/(loss) and comprehensive income/(loss) presented in the statements of operations for the three month periods ended March 31, 2022 and 2021. Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The CODM is the Company’s chief executive officer. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s singular concentration is focused on the development of its virtual reality surgical system. Emerging Growth Company Status The Company is an “emerging growth company,” (“EGC”) as defined in the Jumpstart Our Business Startups Act, (the “JOBS Act”), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act and has elected to use the extended transition period for complying with new or revised accounting standards. As a result of this election, the Company’s financial statements may not be comparable to companies that comply with public company Financial Accounting Standards Board (“FASB”) standards’ effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an offering or such earlier time that it is no longer an EGC. Recently Issued Accounting Standards In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326) Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments

Acquisition

Acquisition	3 Months Ended
	Mar. 31, 2022
Business Combinations [Abstract]
ACQUISITION	3. AcquisitIon On September 17, 2021, the Company and D8 consummated the Business Combination with Legacy Vicarious Surgical surviving the merger as a wholly-owned subsidiary of D8. Upon the consummation of the Business Combination, each share of Legacy Vicarious Surgical issued and outstanding was exchanged for 3.29831 shares (the “Exchange Ratio”) of the Company’s common stock (the “Merger Consideration”). Upon the closing of the Business Combination, D8’s certificate of incorporation was amended and restated to, among other things, increase the total number of authorized shares of all classes of capital stock to 143,931,076 shares, of which 124,141,216 were designated as Class A common stock and 19,789,860 were designated as Class B common stock both having a par value of $0.0001 per share. In connection with the execution of the definitive agreement for the Business Combination, D8 entered into separate subscription agreements (each a “Subscription Agreement”) with a number of investors (each a “Subscriber”), pursuant to which the Subscribers agreed to purchase, and D8 agreed to sell to the Subscribers, an aggregate of 14,200,000 shares of the Company’s common stock, for a purchase price of $10.00 per share and an aggregate purchase price of $142,000, in a private placement pursuant to the Subscription Agreements (the “PIPE financing”). The PIPE financing closed simultaneously with the consummation of the Business Combination. The Business Combination is accounted for as a reverse recapitalization in accordance with US GAAP. Under this method of accounting, D8 was treated as the “acquired” company for financial accounting purposes. See Note 1, “Nature of Business and Basis of Presentation” for further details. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Vicarious Surgical issuing stock for the net assets of D8, accompanied by a recapitalization. The net assets of D8 are stated at historical cost, with no goodwill or other intangible assets recorded. The following table reconciles the elements of the Business Combination to the statement of cash flows and the statement of changes in equity for the year ended December 31, 2021. Recapitalization Cash - D8’s trust and cash (net of redemptions) $ 77,993 Cash - PIPE financing 142,000 Less: Transaction costs and advisory fees (29,569 ) Net proceeds from reverse recapitalization 190,424 Less: Warrant liabilities assumed (93,110 ) Net assets and liabilities assumed in reverse recapitalization $ 97,314 The number of shares of common stock issued immediately following the consummation of the Business Combination was as follows: Number of Common stock, outstanding prior to the Business Combination 34,500,000 Less: Redemption of D8 shares (26,745,028 ) D8 Public Shares 7,754,972 D8 Sponsor Shares 8,625,000 Shares issued in PIPE financing 14,200,000 Business combination and PIPE financing shares 30,579,972 Legacy Vicarious Surgical shares (1) 88,042,340 Total shares of common stock immediately after Business Combination 118,622,312 (1) The number of Legacy Vicarious Surgical shares was determined from the shares of Legacy Vicarious Surgical shares outstanding immediately prior to the closing of the Business Combination converted at the Exchange Ratio of 3.29831. All fractional shares were rounded down.

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	4. PROPERTY AND EQUIPMENT, NET Property and equipment, net consist of the following: Estimated March 31, December 31, Useful Lives 2022 2021 Machinery and equipment 3 to 5 years $ 1,255 $ 957 Furniture and fixed assets 3 to 7 years 285 186 Computer hardware and software 3 years 494 259 Leasehold improvements Lesser of lease term or asset life 2,821 1,432 Total property and equipment 4,855 2,834 Less accumulated depreciation (768 ) (584 ) Property and equipment, net $ 4,087 $ 2,250 In connection with the Waltham lease, the Company received $840 related to leasehold improvements funded by its landlord. These leasehold improvements are being depreciated over the shorter of the lease term or each asset’s life. The $840 amount paid to vendors by the landlord has been included leasehold improvements. Depreciation expense for the three months ended March 31, 2022 and year ended December 31, 2021 was $184 and $316 respectively. Machinery with a gross value of $232 was acquired for cash of $47 and equipment loans of $185 in 2019. This machinery had accumulated amortization of $168 and $155 at March 31, 2022 and December 31, 2021, respectively.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	5. FAIR VALUE MEASUREMENTS The following fair value hierarchy table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the fair value hierarchy of the inputs the Company utilized to determine such fair value: March 31, 2022 Quoted Prices in Active Significant Markets for Other Significant (Level 1) (Level 2) (Level 3) Total Assets: Money market funds $ 154,208 $ — $ — $ 154,208 Total assets $ 154,208 $ — $ — $ 154,208 Liabilities: Warrant liabilities - public warrants $ 14,316 $ — $ — $ 14,316 Warrant liabilities - private warrants — — 14,976 14,976 Total liabilities $ 14,316 $ — $ 14,976 $ 29,292 December 31, 2021 Quoted Prices in Active Significant Markets for Other Significant (Level 1) (Level 2) (Level 3) Total Assets: Money market funds $ 171,196 $ — $ — $ 171,196 Total assets $ 171,196 $ — $ — $ 171,196 Liabilities: Warrant liabilities - public warrants $ 37,085 $ — $ — $ 37,085 Warrant liabilities - private warrants — — 52,936 52,936 Total liabilities $ 37,085 $ — $ 52,936 $ 90,021 Money market funds are classified as cash and cash equivalents. The fair value of Public Warrants was determined from their value trading on the public markets. The fair value of Private Placement Warrants was calculated using the Black-Scholes Option Pricing Model. The significant assumptions used in the model were the Company’s stock price, exercise price, expected term, volatility, interest rate, and dividend yield. For the three months ended March 31, 2022, the Company recognized a gain to the statement of operations resulting from a decrease in the fair value of liabilities of $60.7 million presented as change in fair value of warrant liabilities on the accompanying statement of operations. The Company estimates the volatility of its warrants based on implied volatility from the Company’s publicly traded warrants and from historical volatility of select peer companies’ common stock that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero. The following table provides quantitative information regarding the inputs used in determining the fair value of the Company’s Level 3 liabilities: As of As of Private Placement Warrants March 31, December 31, Volatility 59 % 60.0 % Stock price $ 5.06 $ 10.62 Expected life of options to convert 4.5 years 4.7 years Risk-free rate 2.4 % 1.2 % Dividend yield 0.00 % 0.00 % The following table shows the change in number and value of the warrants since December 31, 2021: Public Private Total Shares Value Shares Value Shares Value December 31, 2021 17,248,621 $ 37,085 10,400,000 $ 52,936 27,648,621 $ 90,021 Exercised (20 ) (0 ) — — (20 ) (0 ) Change in value — $ (22,769 ) — $ (37,960 ) — $ (60,728 ) March 31, 2022 17,248,601 $ 14,316 10,400,000 $ 14,976 27,648,601 $ 29,292

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2022
Accrued Expenses and Other Current Liabilities [Line Items]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES The following table summarizes the Company’s components of accrued expenses and other current liabilities: As of March December 31, Compensation and benefits related $ 1,883 $ 3,233 Professional services and other 1,162 865 Accrued expenses $ 3,045 $ 4,098

Debt

Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
DEBT	7. DEBT Term Loan In October 2020, the Company entered into a term loan that provided the Company with the ability to borrow up to $3.5 million with any amounts borrowed becoming due on April 1, 2024. The loan consisted of up to two tranches; a $1.5 million tranche which became available to the Company upon the close of the loan agreement in October 2020 and was available to the Company to draw through March 31, 2021 and a second tranche of $2.0 million which became available to the Company through September 30, 2021, upon the Company’s successful achievement of a milestone related to the development of the Company’s surgical robot. Although the milestone was achieved, the Company chose not to draw down the $2.0 million tranche. The term loan was interest-only through September 30, 2021, at which time the Company made the first of 30 equal monthly payments of principal plus interest. The term loan bears interest at a floating rate equal to the Prime Rate, but not less than a minimum rate of 3.25%. In addition, the final payment made at the earlier of the maturity of the loan or its termination is to include a deferred interest payment of 7.5% of the amount borrowed, resulting in a minimum annual rate of 5.98% to be paid to the lender. In the event the Company chooses to repay the term loan prior to the first anniversary of the term loan closing, a prepayment fee of 3% of the outstanding principal balance will apply. The prepayment fee is reduced to 2% if paid after the first anniversary date but before the second anniversary date and then is 1% thereafter. The prepayment fee does not apply if the Company and the bank agree to refinance the loan prior to maturity. The loan has no financial covenants but does contain monthly reporting requirements and gives the lender a first priority lien on all Company assets. In March 2021, the Company borrowed the first tranche of $1.5 million. As of March 31, 2022 and December 31, 2021, $1.2 million and $1.4 million, respectively was outstanding on the term loan. Deferred Financing Costs In connection with the term loan, the Company incurred $0.1 million in expenses, inclusive of the warrant expense, which are netted against the long-term portion of the term loan proceeds. The Company is amortizing these costs over the life of the borrowing. In the three months ended March 31, 2022 and 2021, $66 and $0, respectively of capitalized costs had been amortized to interest expense. Common Stock Warrant In connection with the term loan, the Company issued the lender a warrant to purchase 254,794 shares of common stock at $0.41 per share. The common stock warrant was exercisable for 10 years from the date of issuance, was structured to survive a merger or acquisition (except all-cash and/or public stock acquisitions) and allowed for cashless exercise in whole or part. The fair value of the common stock warrant was $0.33 per share at the grant date, and the Company recorded a total of $85 in deferred financing costs associated with the warrant issuances which are netted against the long-term portion of the term loan proceeds. At the time of the Company’s recapitalization, the lender elected to cashless exercise the warrants resulting in the net issuance of 146,577 shares of common stock. The remaining 108,217 warrants were cancelled as the Company elected not to draw down the second tranche. Equipment Loans In March 2019, the Company entered into two equipment loans with a vendor for the purchase of manufacturing machinery. The equipment loans had an aggregate principal balance of $185 at inception, with forty-eight equal monthly payments of principal and interest due beginning ninety days after taking possession of the machinery. The equipment loans are collateralized by the underlying machinery. As of March 31, 2022 and December 31, 2021, the aggregate outstanding principal balance of the equipment loans was $4 and $16, respectively, net of current portion of $47. The following table represents the future payments required under the noncancellable equipment agreements and includes interest of $4: Years Ended December 31, 2022, $ 38 2023 17 Total future equipment payments $ 55

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	8. COMMITMENTS AND CONTINGENCIES Legal Proceedings—From time to time, the Company may face legal claims or actions in the normal course of business. At each reporting date, the Company evaluates whether a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to its legal proceedings.

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Disclosure Text Block [Abstract]
LEASES	9. LEASES On January 1, 2022, we adopted Accounting Standards Update (“ASU”) 2016-02 and all subsequent amendments, collectively codified in ASC Topic 842, “Leases” (“Topic 842”). The guidance requires modified retrospective adoption, either at the beginning of the earliest period presented or at the beginning of the period of adoption. We elected to apply the guidance at the beginning of the period of adoption and recorded right-of-use (ROU) leased assets of $14.3 million. In conjunction with this, we recorded lease liabilities, which had been discounted at our incremental borrowing rates, of $15.9 million. The impact of our adoption of Topic 842 on our current and deferred income taxes was immaterial. The adoption of ASC 842 had no effect on retained earnings. The Company leases its office facility under noncancelable operating lease agreements expiring in December 2023 and February 2029. Rent expense for the three months ended March 31, 2022 was $565 and for the three months ended March 31, 2021 was $113. Rent expense for the year ended December 31, 2021 was $1,447. A summary of the components of lease costs for the Company under ASC 842 for the three months ended March 31, 2022 and under ASC 840 for the three months ended March 31, 2021 were as follows: March 31, Lease costs 2022 2021 Operating lease costs $ 565 $ 113 Total lease costs $ 565 $ 113 Supplemental disclosure of cash flow information related to leases was as follows: March 31, 2022 Cash paid for amounts included in the measurement of operating lease liabilities (operating cash flows) $ 181 The weighted-average remaining lease term and discount rate were as follows: March 31, 2022 Weighted-average remaining lease term (in years) 10 Weighted-average discount rate 8.74 % The following table presents the maturity of the Company’s operating lease liabilities as of March 31, 2022: Years Ended December 31, 2022, $ 1,463 2023 2,162 2024 2,286 2025 2,358 2026 2,430 Thereafter 13,931 Total future minimum lease payments $ 24,630 Less imputed interest (8.530 ) Carrying value of lease liabilities $ 16,100

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	10. INCOME TAXES For the three month period ended March 31, 2022 and the year ended December 31, 2021, the Company did not record a tax provision as the Company did not earn any taxable income in either period and maintains a full valuation allowance against its net deferred tax assets.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
STOCKHOLDERS’ EQUITY	11. STOCKHOLDERS’ EQUITY Authorized Shares At March 31, 2022, the Company’s authorized shares consisted of 300,000,000 shares of Class A common stock, $0.0001 par value; and 22,000,000 shares of Class B common stock, $0.0001 par value; and 1,000,000 shares of preferred stock, par value of $0.0001 per share. Legacy Vicarious Surgical Preferred Stock In connection with the Business Combination, Legacy Vicarious Surgical’s Convertible Preferred Stock (“Legacy Convertible Preferred Stock”), previously classified as mezzanine was retroactively adjusted, converted into Common Stock, and reclassified to permanent equity as a result of the reverse recapitalization. As of March 31, 2022, there were no Legacy Convertible Preferred Stock authorized, issued or outstanding. The following table summarizes details of Legacy Convertible Preferred Stock authorized, issued and outstanding immediately prior to the Business Combination: Prior to Business Combination Shares Legacy Convertible Preferred Stock Authorized Issued and Preferred Series A Legacy Convertible Preferred Stock, $0.0001 par value 16,740,853 16,740,854 $ 6,477 Series A1 Legacy Convertible Preferred Stock, $0.0001 par value 26,107,321 26,107,321 16,678 Series A2 Legacy Convertible Preferred Stock, $0.0001 par value 10,036,853 10,036,853 9,995 Series A3 Legacy Convertible Preferred Stock, $0.0001 par value 18,267,057 13,665,901 13,520 Total 71,152,084 66,550,929 $ 46,670 The following describes the rights and preferences of the Company’s Legacy Convertible Preferred Stock prior to the conversion in the Business Combination: Voting Dividends Liquidation Conversion Redemption Common Stock Classes of Common Stock Class A common stock receive 1 vote per share. Subject to preferences that may be applicable to any outstanding preferred stock, the holders of shares of Class A common stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by the board of directors out of funds legally available for such purposes. In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, the holders of Class A common stock are entitled to share ratably in all assets remaining after payment of our debts and other liabilities, subject to prior distribution rights of preferred stock or any class or series of stock having a preference over the Class A common stock, then outstanding, if any. Class B common stock receives 20 votes per share and converts into Class A at a one-to-one conversion rate per share. Holders of Class B common stock will share ratably together with each holder of Class A common stock, if and when any dividend is declared by the board of directors. Holders of Class B common stock have the right to convert shares of their Class B common stock into fully paid and non-assessable shares of Class A common stock, on a one-to-one basis, at the option of the holder at any time. Upon the occurrence of certain events, holders of Class B common stock automatically convert into Class A common stock, on a one-to-one basis. In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, the holders of Class B common stock are entitled to share ratably in all assets remaining after payment of our debts and other liabilities, subject to prior distribution rights of preferred stock or any class or series of stock having a preference over the Class B common stock, then outstanding, if any. Restricted Stock Agreements As of January 30, 2021 the shares were fully vested and on September 17, 2021, in connection with the recapitalization the shares were converted to Class B common stock. In 2021, subsequent to the recapitalization, the Company issued 749,691 restricted stock units (“RSUs”) of Class A common stock to employees and members of the board of directors. The RSUs vest over a four-year period. The activity for common stock subject to vesting for the three months ended March 31, 2022, is as follows: Shares Weighted Balance of unvested shares - January 1, 2022 698,051 $ 12.54 Granted 84,744 $ 5.81 Vested (56,716 ) $ 11.86 Balance of unvested shares - March 31, 2022 726,079 $ 11.81 The total stock-based compensation related to the RSUs during the three months ended March 31, 2022, was $0.8 million. As of March 31, 2022, the total unrecognized stock-based compensation expense related to unvested RSUs aggregated $8.1 million and is expected to be recognized over a weighted average period of 3.2 years. The aggregate intrinsic value of the awards granted during the three months ended March 31, 2022 and 2021, was $0.7 million and $0.0 million, respectively. The aggregate intrinsic value of the awards vested during the three months ended March 31, 2022 and 2021, was $0.6 million and $0.4 million, respectively. The aggregate intrinsic value of RSUs outstanding at March 31, 2022 was $6.2 million. Preferred Stock Preferred stock shares authorized may be issued from time to time in one or more series, with each series terms, voting, dividend, conversion, redemption, liquidation and other rights to be determined by the Board of Directors at the time of issuance. Warrants In D8’s initial public offering, on July 17, 2020 it sold units at a price of $10.00 per unit, which consisted of one D8 Class A ordinary share, $0.0001 par value, and one-half of a redeemable warrant (each a “Public Warrant”). On July 17, 2020, simultaneously with the closing of its initial public offering, D8 consummated the private placement of 8,000,000 Private Placement Warrants (the “Private Placement Warrants”), each exercisable to purchase one D8 Class A ordinary share at $11.50 per share, at a price of $1.00 per Private Placement Warrant. On July 24, 2020, simultaneously with the sale of D8’s over-allotment units, D8 consummated a private sale of an additional 900,000 Private Placement Warrants. In connection with the Business Combination, 1,500,000 additional Private Placement Warrants were issued upon conversion of D8 working capital loans. In connection with the Business Combination, each issued and outstanding D8 Class A ordinary share automatically converted into one share of Class A common stock. Each warrant is exercisable to purchase one share of Class A common stock at $11.50 per share. As of March 31, 2022, the Company had 17,248,601 Public Warrants and 10,400,000 Private Placement Warrants outstanding. The Public Warrants became exercisable at $11.50 per share 30 days after the completion of the September 17, 2021 Business Combination. If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. The Company filed a registration statement with the SEC that was declared effective as of October 22, 2021 covering the shares of Class A common stock issuable upon exercise of the warrants and is maintaining a current prospectus relating to those shares of Class A common stock until the warrants expire, are exercised or redeemed, as specified in the warrant agreement. The warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. Redemption of warrants when the price per share of Class A common stock equals or exceeds $18.00. ● in whole and not in part; ● at a price of $0.01 per warrant; ● upon a minimum of 30 days’ prior written notice of redemption; and ● if, and only if, the last reported sale price of Class A common stock equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. Redemption of warrants when the price per share of Class A common stock equals or exceeds $10.00 ● in whole and not in part; ● at a price of $0.10 per warrant; ● upon a minimum of 30 days’ prior written notice of redemption; provided ● if, and only if, the last reported sale price of Class A common stock shares equals or exceeds $10.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in D8’s initial public offering, except that the Private Placement Warrants and the shares of Class A common stock issuable upon exercise of the Private Placement Warrants, so long as they are held by the Sponsor or its permitted transferees, (i) are not redeemable by the Company, (ii) could not (including the shares of Class A common stock issuable upon exercise of these warrants), subject to certain limited exceptions, be transferred, assigned or sold by the holders until 30 days after the completion of the initial Business Combination, (iii) may be exercised by the holders on a cashless basis and (iv) are entitled to registration rights. If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by the holders on the same basis as the Public Warrants.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2022
Stock-Based Compensation [Abstract]
STOCK-BASED COMPENSATION	12. Stock-based Compensation In September 2021, the Company’s stockholders approved the 2021 Equity Incentive Plan (the “2021 Plan”), pursuant to which 6,590,000 shares of Class A common stock were reserved for future equity grants under the 2021 Plan and 11,794,074 shares of Class A common stock were reserved for issuance under the 2021 Plan upon exercise of outstanding option awards assumed by the Company in connection with the Business Combination. 2014 Plan 2021 Plan The Company grants stock options to employees at exercise prices deemed by the Board of Directors to be at least equal to the fair market value of the common stock at the time of grant. The fair value of the Company’s stock options and warrants on the date of grant is determined by a Black-Scholes pricing model utilizing key assumptions such as common stock price, risk-free interest rate, dividend yield, expected volatility and expected life. The Company’s estimates of these assumptions are primarily based on the fair value of the Company’s stock, historical data, peer company data and judgement regarding future trends. Prior to the Business Combination, the fair value of the Company’s common stock was determined by the Board of Directors at each award grant date based upon a variety of factors, including the results obtained from a third-party valuation, the Company’s financial position and historical financial performance, the status of technological development within the Company’s proposed products, the illiquid nature of the common stock, arm’s-length sales of the Company’s capital stock, including convertible preferred stock, the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event, among others, as the Company’s common stock was not actively traded. Since becoming a publicly traded company, the Company uses its publicly traded stock price as the fair value of its common stock During the three months ended March 31, 2022 and March 31, 2021, the Company granted options to purchase 466,272 and 3,495,410 shares, respectively, of Class A common stock, to employees and consultants with a fair value of $1,719 and $4,125 respectively, calculated using the Black-Scholes option-pricing model with the following assumptions: Three Months Three Months March 31, March 31, 2022 2021 Risk-free interest rate 1.94% - 1.95 % 0.175 % Expected lives, in years 5.89 - 6.07 5.20 - 6.11 Dividend yield — % — % Expected volatility 69.68% - 70.02 % 69.66% - 71.02 % Fair value of Common Stock $ 5.85 $ 6.26 The risk-free interest rate assumption is based upon observed interest rates appropriate for the term of the related stock options. The expected life of employee and non-employee stock options was calculated using the average of the contractual term of the option and the weighted-average vesting period of the option, as the Company does not have sufficient history to use an alternative method to calculate an expected life for employees. The Company does not pay a dividend and is not expected to pay a dividend in the foreseeable future. Expected volatility for the Company’s common stock was determined based on an average of the historical volatility of a peer group of similar public companies. At March 31, 2022, the total gross unrecognized stock-based compensation expense related to unvested stock options aggregated $18,937. The costs remaining as of March 31, 2022 are expected to be recognized over a weighted-average period of 2.85 years. Total stock-based compensation expense related to all of the Company’s stock-based awards granted is reported in the statements of operations as follows: For the Three Months Ended 2022 2021 Research and development $ 473 $ 111 Sales and marketing 294 15 General and administrative 1,510 130 Total $ 2,277 $ 256 The Company plans to generally issue previously unissued shares of common stock for the exercise of stock options. There were 4,051,220 shares available for future equity grants under the 2021 Plan at March 31, 2022. The option activity of the 2021 Plan for the three months ended March 31, 2022, is as follows: Remaining Exercise Contractual Life Options Price (in Years) Outstanding at January 1, 2022 12,009,768 $ 2.92 7.76 Granted 466,272 5.85 9.88 Exercised (1,342,852 ) 0.25 5.99 Repurchased, cancelled, forfeited, or expired (96,103 ) 2.29 - Options vested and expected to vest at March 31, 2022 11,037,085 $ 3.38 8.10 The weighted-average grant date fair value for options granted during the three months ended March 31, 2022 and March 31, 2021 was $3.69 and $3.89, respectively. The aggregate intrinsic value of options exercised during the three months ended March 31, 2022 and March 31, 2021 $7,295 and $34, respectively. Common Stock Reserved for Future Issuance As of March 31, 2022 and December 31, 2021, the Company has reserved the following shares of Class A common stock for future issuance (in thousands): As of March 31, December 31, 2022 2021 Common stock options outstanding 11,037 12,010 Restricted stock units outstanding 726 698 Shares available for issuance under the 2021 Plan 4,051 4,506 Public warrants 17,249 17,249 Private warrants 10,400 10,400 Total shares of authorized Common Stock reserved for future issuance 43,463 44,863

Employee Retirement Plan

Employee Retirement Plan	3 Months Ended
	Mar. 31, 2022
Retirement Benefits [Abstract]
EMPLOYEE RETIREMENT PLAN	13. EMPLOYEE RETIREMENT PLAN The Company maintains the Vicarious Surgical Inc. 401(k) plan, under Section 401(k) of the Internal Revenue Code, covering all eligible employees. Employees of the Company may participate in the 401(k) Plan after three months of service and must be 21 years of age. The Company offers a company-funded matching contribution which totaled $207 for the three month period ended March 31, 2022, and $75 for the three month period ended March 31, 2021.

Net Income_(Loss) Per Share

Net Income/(Loss) Per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
NET INCOME/(LOSS) PER SHARE	14. Net Income/(Loss) Per Share The Company computes basic income/(loss) per share using net income/(loss) attributable to Vicarious Surgical Inc. common stockholders and the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options and stock-based awards where the conversion of such instruments would be dilutive. For the 2022 2021 Numerator for basic and diluted net loss per share: Net income/(loss) $ 42,527 $ (5,231 ) Denominator for basic net gain/(loss) per share: Weighted average shares 120,279,819 87,508,933 Denominator for diluted net gain/(loss) per share: Weighted average shares 127,593,181 87,508,933 Net income/(loss) per share of Class A and Class B common stock – basic $ 0.35 $ (0.06 ) Net income/(loss) per share of Class A and Class B common stock – diluted $ 0.33 $ (0.06 ) For the three months ended March 31, 2022, 30,821,956 shares, consisting of non-vested stock options, non-vested restricted stock awards, and warrants were excluded from the denominator for the calculation of diluted net income per share because these shares inclusion would be antidilutive.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods presented. Estimates are used for, but are not limited to, the Company’s ability to continue as a going concern, depreciation of property and equipment, fair value of financial instruments, and contingencies. Actual results may differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments US GAAP requires disclosure of fair value information about financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate that value. The framework provides a fair value hierarchy that prioritizes the inputs for the valuation techniques. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements) and minimizes the use of unobservable inputs. The most observable inputs are used, when available. The three levels of the fair value hierarchy are described as follows: Level 1 Level 2 Level 3 The carrying values of prepaid expenses, right of use assets, accounts payable, and accrued expenses approximate their fair values due to the short-term nature of the instruments. The fair value of Public Warrants was determined from their trading value on public markets. The fair value of Private Placement Warrants was calculated using the Black-Scholes Option Pricing Model since these instruments do not have the early redemption feature.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents consist of checking accounts and money market funds. The Company considers all highly liquid investments with an original maturity of 90 days or less at the date of purchase to be cash equivalents.
Restricted Cash	Restricted Cash The Company has an agreement to maintain a cash balance of $936 and $1,055 at March 31, 2022 and December 31, 2021, respectively as collateral for letters of credit related to the Company’s leases. The balance is classified as long-term on the Company’s balance sheets as the lease periods end beginning in December 2023 through February 2029.
Short-Term Investments	Short-Term Investments All of the Company’s investments, which consist of certificates of deposit, are classified as available for sale and are carried at fair value. There were no unrealized gains for the three month period ended March 31, 2022 and year ended December 31, 2021. The Company holds no short-term investments as of March 31, 2022.
Concentrations of Credit Risk and Off-Balance-Sheet Risk	Concentrations of Credit Risk and Off-Balance-Sheet Risk The Company has no significant off-balance-sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist mainly of cash and cash equivalents. The Company maintains its cash and cash equivalents principally with accredited financial institutions of high-credit standing.
Warrant Liabilities	Warrant Liabilities The Company does not use derivative instruments to hedge its exposures to cash flow, market or foreign currency risks. Management evaluates all of the Company’s financial instruments, including issued warrants to purchase its Class A common stock, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. As part of the Business Combination, the Company assumed 17,249,991 Public Warrants that are exercisable to purchase shares of Class A common stock to investors as well as 10,400,000 Private Placement Warrants. All of the Company’s outstanding warrants are recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, the Company recognizes the warrants as liabilities at fair value and adjusts the warrant liability to fair value at each reporting period. The liabilities are subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the statement of operations. The fair value of Public Warrants was determined from their trading value on public markets. The fair value of Private Placement Warrants was calculated using the Black-Scholes Option Pricing Model since these instruments do not have the early redemption feature.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in the determination of net loss. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. The Company does not believe that any events have occurred through March 31, 2022, that would indicate its long-lived assets are impaired.
Leases	Leases Prior to January 1, 2022, the Company accounted for leases under Accounting Standards Codification (“ASC”) 840, Leases Effective January 1, 2022, the Company adopted Accounting Standards Update (“ASU”) 2016-02, Leases The adoption of ASC 842 requires lessees to record a lease liability which is initially measured at the present value of all future lease payments, and a right-of-use asset, associated with operating leases, is recorded on the Company’s balance sheet. The standard also requires a single lease expense to be recognized within the statement of operations on a straight-line basis over the lease term. The effects of the Company’s January 1, 2022 adoption of ASC 842 resulted in the Company recording lease liabilities and right-of-use assets associated with its operating leases on its consolidated balance sheet and did not have any effect on the consolidated statement of operations or consolidated statement of cash flows. As part of the adoption of ASC 842, the Company elected to use the package of practical expedients permitted under the transition guidance. As a result, the Company did not reassess (i) whether any expired or existing contracts are or contain leases, (ii) the lease classification for any expired or existing leases, or (iii) initial direct costs for any existing leases. For each asset class and the related lease agreements in which the Company is the lessee that include lease and non-lease components, the Company made an election about the use of the practical expedient on all leases entered into or modified after January 1, 2022 to combine lease and non-lease components. Additionally, the Company elected to not record on the balance sheet leases with a term of twelve months or less.
Guarantees and Indemnifications	Guarantees and Indemnifications As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through March 31, 2022, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related liabilities have been established.
Research and Development	Research and Development Research and development costs are expensed in the period incurred. Research and development costs include payroll and personnel expenses, consulting costs, software and webservices, legal, raw materials and allocated overhead such as depreciation and amortization, rent and utilities. Advance payments for goods and services to be used in future research and development activities are recorded as prepaid expenses and are expensed over the service period as the services are provided or when the goods are consumed.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for all stock-based compensation, including stock options and warrants issued as compensation for services, at fair value and recognizes stock-based compensation expense for those equity awards, net of actual forfeitures, over the requisite service period, which is generally the vesting period of the respective award. The fair value of the Company’s stock options and warrants on the date of grant is determined by a Black-Scholes pricing model utilizing key assumptions such as stock price, expected volatility and expected term. The Company’s estimates of these assumptions are primarily based on the fair value of the Company’s stock, historical data, peer company data and judgment regarding future trends. Prior to becoming a publicly traded company, the fair value of the Company’s common stock was determined by the Board of Directors at each award grant date based upon a variety of factors, including the results obtained from an independent third-party valuation, the Company’s financial position and historical financial performance, the status of technological developments within the Company’s proposed products, the illiquid nature of the common stock, arm’s length sales of the Company’s capital stock, including convertible preferred stock, the effect of the rights and preferences of the preferred stockholders, and the prospects of a liquidity event, among others, as the Company’s common stock is was not actively traded. Since becoming a publicly traded company, the Company uses its publicly traded stock price as the fair value of its common stock.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method pursuant to ASC 740, Accounting for Income Taxes The Company recognizes deferred tax assets to the extent that management believes that these assets are more likely than not to be realized in the future. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. The Company provides reserves for potential payments of taxes to various tax authorities related to uncertain tax positions. Amounts recognized are based on a determination of whether a tax benefit taken by the Company in its tax filings or positions is “more likely than not” to be sustained on audit. The amount recognized is equal to the largest amount that is more than 50% likely to be sustained. Interest and penalties associated with uncertain tax positions are recorded as a component of income tax expense.
Net Income/(Loss) Per Share	Net Income/(Loss) Per Share Basic net income/(loss) per share attributable to common stockholders is computed by dividing the net income/(loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted income/(loss) per share attributable to common stockholders is computed by dividing the diluted net income/(loss) attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common stock. For purpose of this calculation, outstanding stock options, restricted stock units and stock warrants are considered potential dilutive common stock and are excluded from the computation of net loss per share as their effect is anti-dilutive. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to be outstanding when their effect is anti-dilutive.
Comprehensive Income/(Loss)	Comprehensive Income/(Loss) There were no differences between net income/(loss) and comprehensive income/(loss) presented in the statements of operations for the three month periods ended March 31, 2022 and 2021.
Segments	Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The CODM is the Company’s chief executive officer. The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company’s singular concentration is focused on the development of its virtual reality surgical system.
Emerging Growth Company Status	Emerging Growth Company Status The Company is an “emerging growth company,” (“EGC”) as defined in the Jumpstart Our Business Startups Act, (the “JOBS Act”), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act and has elected to use the extended transition period for complying with new or revised accounting standards. As a result of this election, the Company’s financial statements may not be comparable to companies that comply with public company Financial Accounting Standards Board (“FASB”) standards’ effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an offering or such earlier time that it is no longer an EGC.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326) Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments

Acquisition (Tables)

Acquisition (Tables)	3 Months Ended
	Mar. 31, 2022
Business Combinations [Abstract]
Schedule of business combination to the statement of cash flow and changes in equity	Recapitalization Cash - D8’s trust and cash (net of redemptions) $ 77,993 Cash - PIPE financing 142,000 Less: Transaction costs and advisory fees (29,569 ) Net proceeds from reverse recapitalization 190,424 Less: Warrant liabilities assumed (93,110 ) Net assets and liabilities assumed in reverse recapitalization $ 97,314
Schedule of number of shares of common stock issued	Number of Common stock, outstanding prior to the Business Combination 34,500,000 Less: Redemption of D8 shares (26,745,028 ) D8 Public Shares 7,754,972 D8 Sponsor Shares 8,625,000 Shares issued in PIPE financing 14,200,000 Business combination and PIPE financing shares 30,579,972 Legacy Vicarious Surgical shares (1) 88,042,340 Total shares of common stock immediately after Business Combination 118,622,312

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of property and equipment, net	Estimated March 31, December 31, Useful Lives 2022 2021 Machinery and equipment 3 to 5 years $ 1,255 $ 957 Furniture and fixed assets 3 to 7 years 285 186 Computer hardware and software 3 years 494 259 Leasehold improvements Lesser of lease term or asset life 2,821 1,432 Total property and equipment 4,855 2,834 Less accumulated depreciation (768 ) (584 ) Property and equipment, net $ 4,087 $ 2,250

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of financial assets measured at fair value on a recurring basis and indicates the fair value hierarchy	March 31, 2022 Quoted Prices in Active Significant Markets for Other Significant (Level 1) (Level 2) (Level 3) Total Assets: Money market funds $ 154,208 $ — $ — $ 154,208 Total assets $ 154,208 $ — $ — $ 154,208 Liabilities: Warrant liabilities - public warrants $ 14,316 $ — $ — $ 14,316 Warrant liabilities - private warrants — — 14,976 14,976 Total liabilities $ 14,316 $ — $ 14,976 $ 29,292 December 31, 2021 Quoted Prices in Active Significant Markets for Other Significant (Level 1) (Level 2) (Level 3) Total Assets: Money market funds $ 171,196 $ — $ — $ 171,196 Total assets $ 171,196 $ — $ — $ 171,196 Liabilities: Warrant liabilities - public warrants $ 37,085 $ — $ — $ 37,085 Warrant liabilities - private warrants — — 52,936 52,936 Total liabilities $ 37,085 $ — $ 52,936 $ 90,021
Schedule of quantitative information regarding Level 3 fair value measurements	As of As of Private Placement Warrants March 31, December 31, Volatility 59 % 60.0 % Stock price $ 5.06 $ 10.62 Expected life of options to convert 4.5 years 4.7 years Risk-free rate 2.4 % 1.2 % Dividend yield 0.00 % 0.00 %
Schedule of the change in number and value of the warrants	Public Private Total Shares Value Shares Value Shares Value December 31, 2021 17,248,621 $ 37,085 10,400,000 $ 52,936 27,648,621 $ 90,021 Exercised (20 ) (0 ) — — (20 ) (0 ) Change in value — $ (22,769 ) — $ (37,960 ) — $ (60,728 ) March 31, 2022 17,248,601 $ 14,316 10,400,000 $ 14,976 27,648,601 $ 29,292

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Accrued Expenses and Other Current Liabilities (Table) [Line Items]
Schedule of accrued expenses and other current liabilities	As of March December 31, Compensation and benefits related $ 1,883 $ 3,233 Professional services and other 1,162 865 Accrued expenses $ 3,045 $ 4,098

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of the future payments required under the noncancellable equipment	Years Ended December 31, 2022, $ 38 2023 17 Total future equipment payments $ 55

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Disclosure Text Block [Abstract]
Schedule of components of lease costs	March 31, Lease costs 2022 2021 Operating lease costs $ 565 $ 113 Total lease costs $ 565 $ 113
Schedule of supplemental disclosure of cash flow information	March 31, 2022 Cash paid for amounts included in the measurement of operating lease liabilities (operating cash flows) $ 181
Schedule of weighted-average remaining lease term and discount rate	March 31, 2022 Weighted-average remaining lease term (in years) 10 Weighted-average discount rate 8.74 %
Schedule of maturity of the Company’s operating lease liabilities	Years Ended December 31, 2022, $ 1,463 2023 2,162 2024 2,286 2025 2,358 2026 2,430 Thereafter 13,931 Total future minimum lease payments $ 24,630 Less imputed interest (8.530 ) Carrying value of lease liabilities $ 16,100

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended	9 Months Ended
	Mar. 31, 2022	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Schedule of convertible preferred stock authorized, issued and outstanding	Prior to Business Combination Shares Legacy Convertible Preferred Stock Authorized Issued and Preferred Series A Legacy Convertible Preferred Stock, $0.0001 par value 16,740,853 16,740,854 $ 6,477 Series A1 Legacy Convertible Preferred Stock, $0.0001 par value 26,107,321 26,107,321 16,678 Series A2 Legacy Convertible Preferred Stock, $0.0001 par value 10,036,853 10,036,853 9,995 Series A3 Legacy Convertible Preferred Stock, $0.0001 par value 18,267,057 13,665,901 13,520 Total 71,152,084 66,550,929 $ 46,670
Schedule of activity for common stock subject to vesting		Shares Weighted Balance of unvested shares - January 1, 2022 698,051 $ 12.54 Granted 84,744 $ 5.81 Vested (56,716 ) $ 11.86 Balance of unvested shares - March 31, 2022 726,079 $ 11.81

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Stock-Based Compensation Tables [Abstract]
Schedule of Black-Scholes option-pricing model	Three Months Three Months March 31, March 31, 2022 2021 Risk-free interest rate 1.94% - 1.95 % 0.175 % Expected lives, in years 5.89 - 6.07 5.20 - 6.11 Dividend yield — % — % Expected volatility 69.68% - 70.02 % 69.66% - 71.02 % Fair value of Common Stock $ 5.85 $ 6.26
Schedule of stock-based awards granted	For the Three Months Ended 2022 2021 Research and development $ 473 $ 111 Sales and marketing 294 15 General and administrative 1,510 130 Total $ 2,277 $ 256
Schedule of option activity of the 2021 Plan	Remaining Exercise Contractual Life Options Price (in Years) Outstanding at January 1, 2022 12,009,768 $ 2.92 7.76 Granted 466,272 5.85 9.88 Exercised (1,342,852 ) 0.25 5.99 Repurchased, cancelled, forfeited, or expired (96,103 ) 2.29 - Options vested and expected to vest at March 31, 2022 11,037,085 $ 3.38 8.10
Schedule of shares of Class A common stock	As of March 31, December 31, 2022 2021 Common stock options outstanding 11,037 12,010 Restricted stock units outstanding 726 698 Shares available for issuance under the 2021 Plan 4,051 4,506 Public warrants 17,249 17,249 Private warrants 10,400 10,400 Total shares of authorized Common Stock reserved for future issuance 43,463 44,863

Net Income_(Loss) Per Share (Ta

Net Income/(Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of basic income/(loss) per share	For the 2022 2021 Numerator for basic and diluted net loss per share: Net income/(loss) $ 42,527 $ (5,231 ) Denominator for basic net gain/(loss) per share: Weighted average shares 120,279,819 87,508,933 Denominator for diluted net gain/(loss) per share: Weighted average shares 127,593,181 87,508,933 Net income/(loss) per share of Class A and Class B common stock – basic $ 0.35 $ (0.06 ) Net income/(loss) per share of Class A and Class B common stock – diluted $ 0.33 $ (0.06 )

Nature of Business and Basis _2

Nature of Business and Basis of Presentation (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Apr. 15, 2021	Mar. 31, 2022
Nature of Business and Basis of Presentation (Details) [Line Items]
Cash		$ 190,424
Transaction costs		$ 29,569
Business Combination [Member]
Nature of Business and Basis of Presentation (Details) [Line Items]
Business combination agreement, description	On April 15, 2021, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with D8 Holdings Corp (“D8”) to effect a business combination between D8 and the Company with the Company surviving the merger as a wholly owned subsidiary of D8 (the “Business Combination”). On September 17, 2021 the Merger Agreement was effected, and each share of Vicarious Surgical Inc. stock was exchanged for 3.29831 shares of D8 common stock. The Company received total proceeds of $77,993 after redemptions. In connection with the Business Combination, D8 entered into subscription agreements with subscribers who agreed to purchase an aggregate of 14,200,000 shares of Class A common stock for a purchase price of $142,000 (the “PIPE”), all of which were issued on the effective date.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Summary of Significant Accounting Policies (Details) [Line Items]
Cash balance	$ 936	$ 1,055
Public warrants	17,249,991
Private placement warrants	10,400,000
Series of Individually Immaterial Business Acquisitions [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Sustained percentage	50.00%

Acquisition (Details)

Acquisition (Details) - USD ($)	1 Months Ended	3 Months Ended
	Sep. 17, 2021	Mar. 31, 2022	Dec. 31, 2021
Acquisition (Details) [Line Items]
Exchange ratio of shares converted into common stock	3.29831	3.29831
Increased total number of authorized shares of all classes of capital stock		143,931,076
Common stock, par value (in Dollars per share)		$ 0.0001
Aggregate shares of common stock		14,200,000
Aggregate purchase price (in Dollars)		$ 142,000
Business Acquisition [Member]
Acquisition (Details) [Line Items]
Aggregate purchase price (in Dollars per share)		$ 10
Class A Common Stock [Member]
Acquisition (Details) [Line Items]
Designated shares of common stock		124,141,216
Common stock, par value (in Dollars per share)		$ 0.0001	$ 0.0001
Class B Common Stock [Member]
Acquisition (Details) [Line Items]
Designated shares of common stock		19,789,860
Common stock, par value (in Dollars per share)		$ 0.0001	$ 0.0001

Acquisition (Details) - Schedul

Acquisition (Details) - Schedule of business combination to the statement of cash flow and changes in equity $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Schedule of business combination to the statement of cash flow and changes in equity [Abstract]
Cash - D8’s trust and cash (net of redemptions)	$ 77,993
Cash - PIPE financing	142,000
Less: Transaction costs and advisory fees	(29,569)
Net proceeds from reverse recapitalization	190,424
Less: Warrant liabilities assumed	(93,110)
Net assets and liabilities assumed in reverse recapitalization	$ 97,314

Acquisition (Details) - Sched_2

Acquisition (Details) - Schedule of number of shares of common stock issued	3 Months Ended
	Mar. 31, 2022USD ($)shares
Schedule of number of shares of common stock issued [Abstract]
Common stock, outstanding prior to the Business Combination	34,500,000
Less: Redemption of D8 shares (in Dollars) | $	$ (26,745,028)
D8 Public Shares	7,754,972
D8 Sponsor Shares	8,625,000
Shares issued in PIPE financing	14,200,000
Business combination and PIPE financing shares	30,579,972
Legacy Vicarious Surgical shares	88,042,340	[1]
Total shares of common stock immediately after Business Combination	118,622,312
[1]	The number of Legacy Vicarious Surgical shares was determined from the shares of Legacy Vicarious Surgical shares outstanding immediately prior to the closing of the business combination converted at the Exchange Ratio of 3.29831. All fractional shares were rounded down.

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Leasehold improvements		$ 840
Non-cash allowance		840
Depreciation expense		184	$ 316
Machinery gross value	$ 232
Cash	47
Equipment loans	$ 185
Accumulated amortization		$ 168	$ 155

Property and Equipment, Net (_2

Property and Equipment, Net (Details) - Schedule of property and equipment, net - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total property and equipment Gross	$ 4,855	$ 2,834
Less accumulated depreciation	(768)	(584)
Property and equipment, net	4,087	2,250
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment Gross	$ 1,255	957
Machinery and equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful life	3 years
Machinery and equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful life	5 years
Furniture and fixed assets [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment Gross	$ 285	186
Furniture and fixed assets [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful life	3 years
Furniture and fixed assets [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful life	7 years
Computer hardware and software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful life	3 years
Total property and equipment Gross	$ 494	259
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment Gross	$ 2,821	$ 1,432
Property and equipment, estimated useful life	Lesser of lease term or asset life

Fair Value Measurements (Detail

Fair Value Measurements (Details) $ in Millions	Mar. 31, 2022USD ($)
Fair Value Disclosures [Abstract]
Fair value of liabilities	$ 60.7

Fair Value Measurements (Deta_2

Fair Value Measurements (Details) - Schedule of financial assets measured at fair value on a recurring basis and indicates the fair value hierarchy - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets:
Money market funds	$ 154,208	$ 171,196
Total assets	154,208	171,196
Liabilities:
Total liabilities	29,292	90,021
Public Warrants [Member]
Liabilities:
Warrant liabilities	14,316	37,085
Private Warrants [Member]
Liabilities:
Warrant liabilities	14,976	52,936
Quoted Prices in Active Markets for Identical Items (Level 1) [Member]
Assets:
Money market funds	154,208	171,196
Total assets	154,208	171,196
Liabilities:
Total liabilities	14,316	37,085
Quoted Prices in Active Markets for Identical Items (Level 1) [Member] | Public Warrants [Member]
Liabilities:
Warrant liabilities	14,316	37,085
Quoted Prices in Active Markets for Identical Items (Level 1) [Member] | Private Warrants [Member]
Liabilities:
Warrant liabilities
Significant Other observable Inputs (Level 2) [Member]
Assets:
Money market funds
Total assets
Liabilities:
Total liabilities
Significant Other observable Inputs (Level 2) [Member] | Public Warrants [Member]
Liabilities:
Warrant liabilities
Significant Other observable Inputs (Level 2) [Member] | Private Warrants [Member]
Liabilities:
Warrant liabilities
Significant Unobservable Inputs (Level 3) [Member]
Assets:
Money market funds
Total assets
Liabilities:
Total liabilities	14,976	52,936
Significant Unobservable Inputs (Level 3) [Member] | Public Warrants [Member]
Liabilities:
Warrant liabilities
Significant Unobservable Inputs (Level 3) [Member] | Private Warrants [Member]
Liabilities:
Warrant liabilities	$ 14,976	$ 52,936

Fair Value Measurements (Deta_3

Fair Value Measurements (Details) - Schedule of quantitative information regarding Level 3 fair value measurements - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Schedule of quantitative information regarding Level 3 fair value measurements [Abstract]
Volatility	59.00%	60.00%
Stock price (in Dollars per share)	$ 5.06	$ 10.62
Expected life of options to convert	4 years 6 months	4 years 8 months 12 days
Risk-free rate	2.40%	1.20%
Dividend yield	0.00%	0.00%

Fair Value Measurements (Deta_4

Fair Value Measurements (Details) - Schedule of the change in number and value of the warrants $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)shares
Fair Value Measurements (Details) - Schedule of the change in number and value of the warrants [Line Items]
Opening balance, Shares | shares	27,648,621
Opening balance, Value | $	$ 90,021
Ending balance, Shares | shares	27,648,601
Ending balance, Value | $	$ 29,292
Exercised, Shares | shares	(20)
Exercised, Value | $	$ 0
Change in value, Shares | shares
Change in value, Value | $	$ (60,728)
Public [Member]
Fair Value Measurements (Details) - Schedule of the change in number and value of the warrants [Line Items]
Opening balance, Shares | shares	17,248,621
Opening balance, Value | $	$ 37,085
Ending balance, Shares | shares	17,248,601
Ending balance, Value | $	$ 14,316
Exercised, Shares | shares	(20)
Exercised, Value | $	$ 0
Change in value, Shares | shares
Change in value, Value | $	$ (22,769)
Private [Member]
Fair Value Measurements (Details) - Schedule of the change in number and value of the warrants [Line Items]
Opening balance, Shares | shares	10,400,000
Opening balance, Value | $	$ 52,936
Ending balance, Shares | shares	10,400,000
Ending balance, Value | $	$ 14,976
Exercised, Shares | shares
Exercised, Value | $
Change in value, Shares | shares
Change in value, Value | $	$ (37,960)

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - Schedule of accrued expenses and other current liabilities - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Schedule of accrued expenses and other current liabilities [Abstract]
Compensation and benefits related	$ 1,883	$ 3,233
Professional services and other	1,162	865
Accrued expenses	$ 3,045	$ 4,098

Debt (Details)

Debt (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended		12 Months Ended
	Mar. 31, 2021	Oct. 31, 2020	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Debt (Details) [Line Items]
Company borrowing		$ 3,500
Tranche, description			The loan consisted of up to two tranches; a $1.5 million tranche which became available to the Company upon the close of the loan agreement in October 2020 and was available to the Company to draw through March 31, 2021 and a second tranche of $2.0 million which became available to the Company through September 30, 2021, upon the Company’s successful achievement of a milestone related to the development of the Company’s surgical robot. Although the milestone was achieved, the Company chose not to draw down the $2.0 million tranche.
Term loan, description			The term loan was interest-only through September 30, 2021, at which time the Company made the first of 30 equal monthly payments of principal plus interest. The term loan bears interest at a floating rate equal to the Prime Rate, but not less than a minimum rate of 3.25%. In addition, the final payment made at the earlier of the maturity of the loan or its termination is to include a deferred interest payment of 7.5% of the amount borrowed, resulting in a minimum annual rate of 5.98% to be paid to the lender. In the event the Company chooses to repay the term loan prior to the first anniversary of the term loan closing, a prepayment fee of 3% of the outstanding principal balance will apply. The prepayment fee is reduced to 2% if paid after the first anniversary date but before the second anniversary date and then is 1% thereafter. The prepayment fee does not apply if the Company and the bank agree to refinance the loan prior to maturity
Outstanding term loan	$ 1,500		$ 1,200		$ 1,400
Incurred expenses			100
Amortized to interest expense			$ 66	$ 0
Exercise of warrant			10 years
Fair value of common stock warrant per share (in Dollars per share)			$ 0.33
Total financing costs			$ 85
Net insurance (in Shares)			146,577
Equipment loans, description			The equipment loans had an aggregate principal balance of $185 at inception, with forty-eight equal monthly payments of principal and interest due beginning ninety days after taking possession of the machinery. The equipment loans are collateralized by the underlying machinery. As of March 31, 2022 and December 31, 2021, the aggregate outstanding principal balance of the equipment loans was $4 and $16, respectively, net of current portion of $47.
Warrant [Member]
Debt (Details) [Line Items]
Issued shares (in Shares)			108,217
Vicarious Surgical US Inc [Member]
Debt (Details) [Line Items]
Debt share purchase (in Shares)			254,794
Per share (in Dollars per share)			$ 0.41

Debt (Details) - Schedule of th

Debt (Details) - Schedule of the future payments required under the noncancellable equipment $ in Thousands	Dec. 31, 2021USD ($)
Schedule of the future payments required under the noncancellable equipment [Abstract]
2022, remaining nine months	$ 38
2023	17
Total future equipment payments	$ 55

Leases (Details)

Leases (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Jan. 01, 2022
Disclosure Text Block [Abstract]
Lease assert				$ 14,300,000
Lease liability,, borrowing rate				$ 15,900,000
Rent expense	$ 565	$ 113	$ 1,447

Leases (Details) - Schedule of

Leases (Details) - Schedule of components of lease costs - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Schedule of components of lease costs [Abstract]
Operating lease costs	$ 565	$ 113
Total lease costs	$ 565	$ 113

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of supplemental disclosure of cash flow information $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Schedule of supplemental disclosure of cash flow information [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities (operating cash flows)	$ 181

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of weighted-average remaining lease term and discount rate	Mar. 31, 2022
Schedule of weighted-average remaining lease term and discount rate [Abstract]
Weighted-average remaining lease term (in years)	10 years
Weighted-average discount rate	8.74%

Leases (Details) - Schedule o_4

Leases (Details) - Schedule of maturity of the Company’s operating lease liabilities	Mar. 31, 2022USD ($)
Schedule of maturity of the Company’s operating lease liabilities [Abstract]
2022, excluding the three months ended March 31, 2022	$ 1,463,000
2023	2,162,000
2024	2,286,000
2025	2,358,000
2026	2,430,000
Thereafter	13,931,000
Total future minimum lease payments	24,630,000
Less imputed interest	(8,530)
Carrying value of lease liabilities	$ 16,100,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Millions	Sep. 17, 2021	Jul. 24, 2020	Jul. 17, 2020	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021
Stockholders' Equity (Details) [Line Items]
Common stock, par value				$ 0.0001
Preferred stock, shares authorized (in Shares)				1,000,000	1,000,000
Preferred stock, par value				$ 0.0001	$ 0.0001
Common stock gross proceeds (in Dollars)				$ 40
Preferred stock share holders percentage				50.00%
Restricted stock agreement, description				In 2014, the Company issued 19,789,860 shares of Legacy Class A common stock to the initial founders of the Company at par that contained a repurchase right by the Company at the lesser of the original purchase price of $0.0001 per share or the then current fair value of the share, which lapsed over a four-year period. In 2016 and 2018 these shares were amended with respect to the lapse of the repurchase rights, such that beginning as of January 2018 60% percent of the shares were vested and the remaining shares vest over a thirty-six month period.
Weighted average period				3 years 2 months 12 days
Aggregate intrinsic value granted (in Dollars)				$ 0.7		$ 0
Aggregate intrinsic value vested (in Dollars)				0.6		$ 0.4
Aggregate intrinsic value of RSU (in Dollars)				$ 6.2
Exercisable to purchase price per share			$ 11.5
Additional shares (in Shares)		900,000
Public warrants (in Shares)				17,249,991
Private placement warrants outstanding (in Shares)				10,400,000
Exercisable price per share	$ 11.5
Warrant description				Redemption of warrants when the price per share of Class A common stock equals or exceeds $18.00. The Company may call the Public Warrants for redemption:    ● in whole and not in part;     ● at a price of $0.01 per warrant;     ● upon a minimum of 30 days’ prior written notice of redemption; and     ● if, and only if, the last reported sale price of Class A common stock equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.  Redemption of warrants when the price per share of Class A common stock equals or exceeds $10.00. The Company may call the Public Warrants for redemption:    ● in whole and not in part;   ●at a price of $0.10 per warrant;   ●upon a minimum of 30 days’ prior written notice of redemption; provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the “fair market value” of the Company’s Class A common stock; and   ●if, and only if, the last reported sale price of Class A common stock shares equals or exceeds $10.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders.  The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in D8’s initial public offering, except that the Private Placement Warrants and the shares of Class A common stock issuable upon exercise of the Private Placement Warrants, so long as they are held by the Sponsor or its permitted transferees, (i) are not redeemable by the Company, (ii) could not (including the shares of Class A common stock issuable upon exercise of these warrants), subject to certain limited exceptions, be transferred, assigned or sold by the holders until 30 days after the completion of the initial Business Combination, (iii) may be exercised by the holders on a cashless basis and (iv) are entitled to registration rights.
IPO [Member]
Stockholders' Equity (Details) [Line Items]
Common stock, par value			0.0001
Price per share			10
Private Placement [Member]
Stockholders' Equity (Details) [Line Items]
Price per share			$ 1
Private placement warrants (in Shares)			8,000,000
Additional shares (in Shares)				1,500,000
Public warrants (in Shares)				17,248,601
Class A Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Common stock, shares authorized (in Shares)				300,000,000
Common stock, par value				$ 0.0001	0.0001
Class A Common Stock [Member] | Warrant [Member]
Stockholders' Equity (Details) [Line Items]
Price per share				$ 11.5
Class B Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Common stock, shares authorized (in Shares)				22,000,000
Common stock, par value				$ 0.0001	$ 0.0001
Series A Preferred Stock [Member]
Stockholders' Equity (Details) [Line Items]
Preferred Stock price per share				0.3926
Preferred stock conversion price per share				0.3926
Series A1 Preferred Stock [Member]
Stockholders' Equity (Details) [Line Items]
Preferred Stock price per share				0.642
Preferred stock conversion price per share				0.642
Series A2 Preferred Stock [Member]
Stockholders' Equity (Details) [Line Items]
Preferred Stock price per share				0.9963
Preferred stock conversion price per share				0.9963
Series A3 Preferred Stock [Member]
Stockholders' Equity (Details) [Line Items]
Preferred Stock price per share				0.9963
Preferred stock conversion price per share				$ 0.9963
Restricted Stock Units (RSUs) [Member]
Stockholders' Equity (Details) [Line Items]
Restricted stock units (in Shares)					749,691
Stock based compensation (in Dollars)				$ 0.8
Aggregate value (in Dollars)				$ 8.1

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of convertible preferred stock authorized, issued and outstanding	Mar. 31, 2022USD ($)shares
Condensed Balance Sheet Statements, Captions [Line Items]
Prior to Business Combination, Authorized	71,152,084
Prior to Business Combination, Issued and outstanding	66,550,929
Prior to Business Combination, Preferred Stock (in Dollars) | $	$ 46,670
Series A Legacy Convertible Preferred Stock [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Prior to Business Combination, Authorized	16,740,853
Prior to Business Combination, Issued and outstanding	16,740,854
Prior to Business Combination, Preferred Stock (in Dollars) | $	$ 6,477
Series A1 Legacy Convertible Preferred Stock [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Prior to Business Combination, Authorized	26,107,321
Prior to Business Combination, Issued and outstanding	26,107,321
Prior to Business Combination, Preferred Stock (in Dollars) | $	$ 16,678
Series A2 Legacy Convertible Preferred Stock [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Prior to Business Combination, Authorized	10,036,853
Prior to Business Combination, Issued and outstanding	10,036,853
Prior to Business Combination, Preferred Stock (in Dollars) | $	$ 9,995
Series A3 Legacy Convertible Preferred Stock [Member]
Condensed Balance Sheet Statements, Captions [Line Items]
Prior to Business Combination, Authorized	18,267,057
Prior to Business Combination, Issued and outstanding	13,665,901
Prior to Business Combination, Preferred Stock (in Dollars) | $	$ 13,520

Stockholders' Equity (Details_2

Stockholders' Equity (Details) - Schedule of activity for common stock subject to vesting	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Schedule of activity for common stock subject to vesting [Abstract]
Shares Subject to Vesting Beginning | shares	698,051
Weighted Average Grant Date Fair Value Beginning | $ / shares	$ 12.54
Shares Subject to Vesting Ending | shares	726,079
Weighted Average Grant Date Fair Value Ending | $ / shares	$ 11.81
Shares Subject to Vesting Granted | shares	84,744
Weighted Average Grant Date Fair Value Granted | $ / shares	$ 5.81
Shares Subject to Vesting Vested | shares	(56,716)
Weighted Average Grant Date Fair Value Vested | $ / shares	$ 11.86

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)	1 Months Ended	3 Months Ended
	Sep. 30, 2021	Mar. 31, 2022	Mar. 31, 2021
Stock-Based Compensation (Details) [Line Items]
Stock-based compensation options and restricted stock vest		25.00%
Grant rate		6.25%
Nonemployees expire		10 years
Granted options to purchase		466,272	3,495,410
Employees and consultants fair value (in Dollars)		$ 1,719	$ 4,125
Stock-based compensation expense (in Dollars)		$ 18,937
Weighted average period		2 years 10 months 6 days
Weighted average grant-date fair value of stock options granted (in Dollars per share)		$ 3.69	$ 3.89
Aggregate intrinsic value of options exercised (in Dollars)		$ 7,295	$ 34
2021 plan [Member]
Stock-Based Compensation (Details) [Line Items]
Class A common stock were reserved for future equity grants	6,590,000
Class A common stock were reserved for issuance	11,794,074
Common stock shares		18,384,074
Shares available for future equity grants		4,051,220
2014 plan [Member]
Stock-Based Compensation (Details) [Line Items]
Stock-based compensation options and restricted stock vest		25.00%
Grant rate		6.25%
Nonemployees expire		10 years
Legacy Vicarious [Member] | 2014 plan [Member]
Stock-Based Compensation (Details) [Line Items]
Common stock shares		19,914,315

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of Black-Scholes option-pricing model - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Stock-Based Compensation (Details) - Schedule of Black-Scholes option-pricing model [Line Items]
Risk-free interest rate		0.175%
Dividend yield
Fair value of Common Stock (in Dollars)	$ 5.85	$ 6.26
Minimum [Member]
Stock-Based Compensation (Details) - Schedule of Black-Scholes option-pricing model [Line Items]
Risk-free interest rate	1.94%
Expected lives, in years	5 years 10 months 20 days	5 years 2 months 12 days
Expected volatility	69.68%	69.66%
Maximum [Member]
Stock-Based Compensation (Details) - Schedule of Black-Scholes option-pricing model [Line Items]
Risk-free interest rate	1.95%
Expected lives, in years	6 years 25 days	6 years 1 month 9 days
Expected volatility	70.02%	71.02%

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of stock-based awards granted - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Schedule of stock-based awards granted [Abstract]
Research and development	$ 473	$ 111
Sales and marketing	294	15
General and administrative	1,510	130
Total	$ 2,277	$ 256

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details) - Schedule of option activity of the 2021 Plan	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Schedule of option activity of the 2021 Plan [Abstract]
Outstanding,Beginning balance, Options | shares	12,009,768
Outstanding,Beginning balance, Exercise Price | $ / shares	$ 2.92
Outstanding,Beginning balance, Remaining Contractual Life	7 years 9 months 3 days
Granted, Options | shares	466,272
Granted, Exercise Price | $ / shares	$ 5.85
Granted, Remaining Contractual Life	9 years 10 months 17 days
Exercised Options | shares	(1,342,852)
Exercised Exercise Price | $ / shares	$ 0.25
Exercised Remaining Contractual Life	5 years 11 months 26 days
Repurchased, cancelled, forfeited, or expired Options | shares	(96,103)
Repurchased, cancelled, forfeited, or expired Exercise Price | $ / shares	$ 2.29
Repurchased, cancelled, forfeited, or expired Remaining Contractual Life
Outstanding, Ending Balance, Options | shares	11,037,085
Outstanding, Ending Balance, Exercise Price | $ / shares	$ 3.38
Outstanding, Ending Balance, Remaining Contractual Life	8 years 1 month 6 days

Stock-Based Compensation (Det_5

Stock-Based Compensation (Details) - Schedule of shares of Class A common stock - shares	Mar. 31, 2022	Mar. 31, 2021
Stock-Based Compensation (Details) - Schedule of shares of Class A common stock [Line Items]
Total shares of authorized Common Stock reserved for future issuance	43,463	44,863
Common stock options outstanding [Member]
Stock-Based Compensation (Details) - Schedule of shares of Class A common stock [Line Items]
Total shares of authorized Common Stock reserved for future issuance	11,037	12,010
Restricted stock units outstanding [Member]
Stock-Based Compensation (Details) - Schedule of shares of Class A common stock [Line Items]
Total shares of authorized Common Stock reserved for future issuance	726	698
Shares available for issuance under the 2021 Plan [Member]
Stock-Based Compensation (Details) - Schedule of shares of Class A common stock [Line Items]
Total shares of authorized Common Stock reserved for future issuance	4,051	4,506
Public warrants [Member]
Stock-Based Compensation (Details) - Schedule of shares of Class A common stock [Line Items]
Total shares of authorized Common Stock reserved for future issuance	17,249	17,249
Private warrants [Member]
Stock-Based Compensation (Details) - Schedule of shares of Class A common stock [Line Items]
Total shares of authorized Common Stock reserved for future issuance	10,400	10,400

Employee Retirement Plan (Detai

Employee Retirement Plan (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Retirement Benefits [Abstract]
Funded matching contribution	$ 207	$ 75

Net Income_(Loss) Per Share (De

Net Income/(Loss) Per Share (Details)	3 Months Ended
	Mar. 31, 2022shares
Earnings Per Share [Abstract]
Dilutive securities	30,821,956

Net Income_(Loss) Per Share (_2

Net Income/(Loss) Per Share (Details) - Schedule of basic income/(loss) per share - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Numerator for basic and diluted net loss per share:
Net income/(loss)	$ 42,527	$ (5,231)
Denominator for basic net gain/(loss) per share:
Weighted average shares	120,279,819	87,508,933
Denominator for diluted net gain/(loss) per share:
Weighted average shares	127,593,181	87,508,933
Net income/(loss) per share of Class A and Class B common stock – basic	$ 0.35	$ (0.06)
Net income/(loss) per share of Class A and Class B common stock – diluted	$ 0.33	$ (0.06)